NCT03571633 2025-11-26
BREASTIMMU02
Centre Leon Berard
Phase 2 Active not recruiting
Clinical Trials
26 trialsNCT05982678 2025-11-26
ANISE
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT04419181 2025-10-14
Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer
University of Rochester
Phase 2 Withdrawn
NCT07179939 2025-09-18
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study
Fudan University
Phase 2 Not yet recruiting
NCT07166367 2025-09-10
Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer
National Cancer Centre, Singapore
Phase 2 Terminated
NCT07116824 2025-08-12
HB1801 Combined Treatment of HER2-positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Not yet recruiting
NCT06973525 2025-08-05
HER2-DM-NACT
Hebei Medical University Fourth Hospital
Phase 2 Not yet recruiting
NCT06445400 2025-08-03
A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT05955170 2025-03-27
TUC-TOC
Institut Curie
Phase 2 Recruiting
NCT06832904 2025-02-18
Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT05306041 2025-02-17
GeparPiPPa
GBG Forschungs GmbH
Phase 2 Recruiting
NCT03125928 2025-01-10
Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
Fox Chase Cancer Center
Phase 2 Active not recruiting
NCT06548178 2024-08-12
T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer
Fudan University
Phase 2 Not yet recruiting
NCT05635487 2024-07-05
A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
Shengjing Hospital
Phase 2 Recruiting
NCT05945368 2023-07-14
A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT05834764 2023-04-28
Pyrotinib in Women With High-risk in Early Stage Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT05429294 2022-06-23
Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038
First Affiliated Hospital Xi'an Jiaotong University
Phase 2 Unknown
NCT05334810 2022-04-19
DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Unknown
NCT05154396 2021-12-13
Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer
ChineseAMS
Phase 2 Unknown
NCT03238495 2021-12-07
HERMET
University of Kansas Medical Center
Phase 2 Unknown
NCT04481932 2020-07-22
Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer
Peking University
Phase 2 Recruiting
NCT03933319 2020-07-08
Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer
ChineseAMS
Phase 2 Unknown
NCT04158856 2019-11-12
SHERO
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Not yet recruiting
NCT04034823 2019-07-26
KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT03919253 2019-04-18
Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study
Hebei Medical University Fourth Hospital
Phase 2 Unknown
NCT03684863 2018-09-26
Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy
Shandong Cancer Hospital and Institute
Phase 2 Unknown